OLANZAPINE POISONING IN CHILDREN : A CASE SERIES

2021 ◽  
pp. 32-33
Author(s):  
Syed Idrees Hassan Sajjad ◽  
Dandu Venkata Satya Sanjay Varma
Keyword(s):  
Atypical Antipsychotic ◽  
Psychotic Disorders ◽  
Case Series ◽  
Altered Sensorium ◽  
Poisoning In Children

Olanzapine is a readily available atypical antipsychotic usually prescribed in adults for psychotic disorders. Olanzapine overdose or poisoning is rarely seen in children. It is often due to accidental intake of drug and sometimes suicidal.We are reporting two case of olanzapine poisoning in children presenting with altered sensorium and pinpoint pupils. The mainstay of treatment of olanzapine poisoning is supportive and symptomatic measures. Both children recovered well and were discharged.

scholarly journals Neuroimmune and Acute Psychotic Disorders had an Overlapping Immune-Signature in Adolescents and Young Adults; A Case Series

2021 ◽  
pp. 17-24
Author(s):  
Jose Irazuzta ◽  
Nicolas Chiriboga Salazar
Keyword(s):  
Psychotic Disorders ◽  
Clinical Symptoms ◽  
Adaptive Immune Response ◽  
Case Series ◽  
Adaptive Immune System ◽  
Treg Cells ◽  
T Cell Subsets ◽  
Clinical Phase ◽  
Adaptive Immune ◽  
Cohort Group

A misguided auto-reactive injury is responsible for diverse types of central nervous system (CNS) conditions. We suspect that, in some of these conditions, the adaptive immune system have a common cellular immune pathogenesis, driven predominantly by T cells, despite variability on the phenotypical clinical presentation. Aim: the main goal of this study is to characterize a portion of the adaptive immune response (AIR) on patients presenting with clinical symptoms compatible with monophasic acute neuroimmune disorders (NID) including Psychotic Disorders (PD). Methodology: flow cytometry with deep immunophenotyping of T effector (Teff) and T regulatory (Treg) cells was performed on peripheral blood obtained during the acute clinical phase and compared it to the one from an age-matched cohort group [Co). Results: our preliminary findings point toward the presence of common “immunosignature” in individuals affected by NID or PD.  We also found a shared dysregulation of immune related neurogenes in NID and PD that were not present in normal cohorts. Conclusions: this preliminary report gives some insights into the underlying shared pathobiology. If we can improve our capacity for early accurate diagnosis and meaningful disease monitoring of pathogenic T cell subsets, we will both expedite disease detection and may serve as a guide the administration of effective immunotherapeutic agents.

Use of atypical antipsychotic drugs in old age psychiatry

2002 ◽  
Vol 8 (1) ◽  
pp. 49-58 ◽  
Author(s):  
Walter Pierre Bouman ◽  
Gill Pinner
Keyword(s):  
Mood Disorders ◽  
Elderly People ◽  
Old Age ◽  
Atypical Antipsychotic ◽  
Antipsychotic Drugs ◽  
Psychotic Disorders ◽  
Psychotropic Medications ◽  
Psychotic Symptoms ◽  
Organic Psychoses ◽  
Old Age Psychiatry

Antipsychotic drugs are among the most widely prescribed psychotropic medications for elderly people, particularly for the 5–8% of patients who are in institutions. The antipsychotics are indicated for treating psychotic disorders, including schizophrenia, delusional disorder, psychotic symptoms in mood disorders and for a number of organic psychoses.

Evaluation of the effectiveness and acceptability of the long-acting oral antipsychotic penfluridol: Illustrative case series

2021 ◽  
pp. 026988112110505
Author(s):  
Danielle Dunnett ◽  
Ebenezer Oloyede ◽  
Oluwakemi Oduniyi ◽  
Barbara Arroyo ◽  
Olubanke Dzahini ◽  
...  
Keyword(s):  
Psychotic Disorders ◽  
Case Series ◽  
Median Number ◽  
Illustrative Case ◽  
The United Kingdom ◽  
Duration Of Illness ◽  
National Health Service Trust ◽  
Oral Antipsychotic ◽  
Long Acting

Aim: In this study, we sought to determine clinical outcomes at 1 year for patients prescribed penfluridol in an inner London National Health Service Trust. Using noninterventional data, we describe the use, effectiveness and safety of this treatment modality. Results: We retrospectively followed up 17 patients prescribed penfluridol as part of routine clinical practice. All patients took penfluridol once weekly. Of these patients, 12 (70.6%) were considered treatment resistant. The average duration of illness for this cohort was 10 years (SD = 6.7). At 1 year, nine (53%) patients remained on treatment. Median survival time was not reached at 1-year follow-up; mean time on penfluridol was 251 days (95% confidence interval (CI), 184–318). The mean number of admissions to hospital in the year following penfluridol initiation was 0.6 compared with 0.8, 1 year before initiation ( p = 0.465). The median number of bed days 1 year before penfluridol initiation was 24, whereas in the year following penfluridol initiation, it was 0 ( p = 0.514). Clinical Implications: Although penfluridol is unlicensed in the United Kingdom, limited data suggest that this long-acting oral therapy has the potential to be used safely and effectively for the treatment of psychotic disorders. However, more data are required to establish the place of penfluridol and other potential long-acting oral antipsychotic formulations in the treatment of psychotic disorders.

Use of Antipsychotic Medications in Australian States and Territories Between July 1995 and December 2001

2003 ◽  
Vol 11 (3) ◽  
pp. 267-272 ◽  
Author(s):  
Jonathan Mond ◽  
Rodney Morice ◽  
Cathy Owen
Keyword(s):  
Atypical Antipsychotic ◽  
Psychotic Disorders ◽  
South Australia ◽  
Prescription Data ◽  
Australian Capital Territory ◽  
First Line ◽  
Antipsychotic Medications ◽  
Defined Daily Doses ◽  
Atypical Antipsychotic Medications ◽  
Year 2000

Objective: To examine trends in the use of oral conventional, depot and atypical antipsychotic medications in Australian States and Territories between 1995 and 2001. Methods: For each 6 month interval between July 1995 and December 2001, prescription data obtained were converted into a measure of drug utilization expressed as the number of defined daily doses per thousand population per day (DDDs/1000/day). Data concerning the major specialty of the prescriber were available for the period 1996–2000. Results: In each State and Territory, use of atypical antipsychotic medications increased markedly while use of oral conventional and depot medications declined. Between July 2001 and December 2001, the proportion of total prescriptions for antipsychotic medications accounted for by prescriptions for atypical medications varied from 63.1% in South Australia to 76.1% in the Australian Capital Territory (ACT). Relative use of atypical medications was higher in the ACT than in other regions, while relative use of depot medications was higher in the Northern Territory than in other regions. During the year 2000, the proportion of prescriptions for oral conventional and depot medications written by general practitioners (GPs) exceeded 75% in all regions other than the ACT. Between 1996 and 2000, the proportion of prescriptions for atypical medications written by GPs increased markedly in all regions but remained lower than for oral conventional and depot medications. Conclusions: Atypical antipsychotic medications have replaced conventional medications as the first-line pharmacological treatment for psychotic disorders in all regions of Australia. Continued expansion of programmes designed to foster collaboration between GPs and mental health services will be essential in achieving optimal prescribing of antipsychotic medications.

Use of Synthetic Cannabinoids in Patients With Psychotic Disorders: Case Series

2014 ◽  
Vol 10 (3) ◽  
pp. 168-173 ◽  
Author(s):  
Andreja Celofiga ◽  
Jure Koprivsek ◽  
Janez Klavz
Keyword(s):  
Psychotic Disorders ◽  
Synthetic Cannabinoids ◽  
Case Series

Atypical (second generation) antipsychotic treatment response in very late-onset schizophrenia-like psychosis

2010 ◽  
Vol 23 (5) ◽  
pp. 742-748 ◽  
Author(s):  
Jamie Scott ◽  
Blaine S. Greenwald ◽  
Elisse Kramer ◽  
Mitchell Shuwall
Keyword(s):  
Treatment Response ◽  
Atypical Antipsychotic ◽  
Second Generation ◽  
Psychotic Disorders ◽  
Age Of Onset ◽  
Late Onset ◽  
Antipsychotic Treatment ◽  
Double Blind ◽  
Positive Treatment ◽  
Second Generation Antipsychotic

ABSTRACTIntroduction: Symptom amelioration in older patients with very late onset schizophrenia-like psychosis (VLOSLP) is often difficult, with limited psychotropic response reports yielding variable findings. Information about atypical (second generation) antipsychotic use in this population is scant.Methods: A consecutive sample of geriatric psychiatry outpatients and inpatients with psychotic disorders were retrospectively identified over a 31-month period based on systematic information abstraction from an electronic medical record (e-record). After exclusion criteria were applied, 8/138 outpatients and 13/362 inpatients met inclusion criteria for VLOSLP and had been naturalistically treated with an atypical antipsychotic during hospitalization or nine months of outpatient care. Mandatorily completed e-record standardized symptom severity response ratings were converted into positive treatment response thresholds.Results: 38% of outpatients and 77% of inpatients (mean age = 76 years for both groups; mean age of onset of psychosis = 70 years for outpatients and 74 years for inpatients) met criteria for positive treatment response to an atypical antipsychotic (either aripiprazole, olanzapine, quetiapine, or risperidone) with sign/symptom amelioration, rather than eradication.Conclusions: Various atypical antipsychotics at geriatric doses yielded a positive treatment response in nearly two-thirds of VLOSLP patients. Patients with less chronic, more severe symptoms responded at a higher rate. Prospective, double-blind, placebo-controlled trials with representative subject samples are needed to validate these preliminary findings.

Sign in / Sign up

Export Citation Format

Share Document